-
2 Walgreens Analysts On Why They're Sidelined After Q3 Earnings
Friday, July 2, 2021 - 12:01pm | 353Read More...The third-quarter report from Walgreens Boots Alliance, Inc. (NASDAQ: WBA) Thursday surpassed Wall Street expectations, with an EPS beat of 19% and reported revenue of $34 billion, $500 million higher than expectations, according to a Raymond James analyst. The Walgreens Analysts:...
-
Credit Suisse Takes Neutral Stance On Mednax, Says Buyout Value Reflected In Share Price
Tuesday, March 27, 2018 - 2:56pm | 372Read More...MEDNAX, Inc. (NYSE: MD) has continued to pursue acquisitions to grow its radiology business segment, making the company a potential private equity target. The company's takeout value appears to be reflected inits valuation, limiting any compelling risk-reward opportunity, according to Credit...
-
Credit Suisse: Growing Enrollment, 2019 Tailwinds For Humana Justify Bullish Stance
Thursday, February 8, 2018 - 1:39pm | 393Read More...Projected 2019 tailwinds led Credit Suisse to upgrade Humana Inc (NYSE: HUM) after the health insurer released a beat-and-raise fourth-quarter report Wednesday. The Analyst Credit Suisse analyst A.J. Rice upgraded shares of Humana from Neutral to Outperform and increased the price target...
-
Credit Suisse: Encompass Health Is The Market Leader In Rehab, Home Health
Wednesday, January 17, 2018 - 4:54pm | 317Read More...Encompass Health Corp (NYSE: EHC) is the sector leader in the rehab and the home health sectors, according to Credit Suisse. The Analyst Credit Suisse's A.J. Rice initiated coverage of Encompass Health Corp with an Outperform rating and $58 price target. The Thesis The company...
-
What Wall Street Thinks Of The $69 Billion CVS-Aetna Deal
Monday, December 4, 2017 - 6:24pm | 1067Read More...Here we have it: the largest deal of 2017. CVS Health Corp (NYSE: CVS) confirmed Monday its agreement to acquire Aetna Inc (NYSE: AET) as a standalone business unit for about $207 per share. The parties intend to close the deal in the second half of 2018 to yield $750 million in near-term synergies...
-
14 Health Care, Managed Care Stocks To Put On Your Radar
Friday, November 3, 2017 - 2:25pm | 543Read More...Credit Suisse has initiated coverage on a number of managed care and health care facilities stocks and is mostly bullish on the space. In the initiation note, analyst A.J. Rice said the fundamentals of managed care stocks are appealing, but their current valuations likely limit upside. The managed...
-
UBS Sees $43-$44 Deal Value For Potential TeamHealth Sale
Wednesday, October 5, 2016 - 10:50am | 294Read More...Shares of TeamHealth Holdings Inc (NYSE: TMH) rose more than 3 percent following a Wall Street Journal report saying the company is exploring a sale to a private-equity firm. UBS says a potential deal may value TeamHealth in a range of $43-$44 per share. The report comes as the company's...
-
UBS Sees PharMerica As A 'Show-Me' Story, Downgrades To Neutral
Monday, March 14, 2016 - 9:04am | 194Read More...UBS’ A.J. Rice downgraded the rating for PharMerica Corporation (NYSE: PMC) from Buy to Neutral, while reducing the price target from $40 to $22. He expects 2016 to be a transitional year for the company. While announcing its 2016 guidance, management cited a number of headwinds:...
-
Analyst Sees Humana Deal At $225-$235/Share
Monday, June 1, 2015 - 4:55pm | 327Read More...Humana Inc (NYSE: HUM)'s third consecutive quarterly earnings miss in April made it vulnerable as a takeover target, an analyst said Monday. Investors expect the company will be acquired for between $225 and $235 a share, according to UBS's A.J. Rice, who said a deal will require nine...
-
Universal Health Services, Inc. (UHS) Maintains Neutral Rating
Wednesday, March 31, 2010 - 3:40pm | 96Read More...Analysts A.J. Rice and Chris Rigg at Susquehanna Financial Group have released an update on Universal Health Services, Inc. (NYSE: UHS). Analysts believe that the company faces a difficult comparison in the first-quarter this year. According to analysts, the general acute business for the company...
